Grippocitron RINOS nasal spray 15 ml.

Description

Grippocitron RINOS COMPOSITION
active ingredients: 1 ml of the drug contains dimethindene maleate 0.25 mg, phenylephrine 2.5 mg

excipients: citric acid monohydrate, sodium phosphate anhydrous sorbitol (E 420) benzalkonium chloride, peppermint oil, purified water.

Grippocitron RINOS DOSAGE FORM
Nasal spray, solution.

Grippocitron RINOS MAIN PHYSICAL AND CHEMICAL PROPERTIES:
clear solution from colorless to slightly yellowish with a specific odor. Opalescence is allowed.

PHARMACOLOGICAL GROUP
Decongestants and other rhinological preparations for topical use. Sympathomimetics, combinations, excluding corticosteroids. ATX code R01A B.

PHARMACOLOGICAL PROPERTIES
Pharmacological. Combined preparation containing phenylephrine and dimethindene.

The drug reduces nasal discharge and helps to cleanse the nasal passages without disturbing the physiological functions of the ciliated epithelium and nasal mucosa.

Dimetindene, an antagonist of histamine H 1 receptors, exhibits antiallergic effect. Effective when used in low doses, well tolerated.

Pharmacokinetics. The drug is applied topically, so its activity does not correlate with the concentration of active substances in the blood plasma.

With accidental oral absorption, the bioavailability of phenylephrine decreased and was approximately 38%, the half-life is approximately 2.5 hours.

The systemic bioavailability of dimethindene after oral administration in solution is approximately 70%, the half-life is about 6:00.

INDICATIONS
Symptomatic treatment in children aged 6 years and older and adults for colds, nasal congestion, acute and chronic rhinitis, seasonal (hay fever) and non-seasonal allergic rhinitis, acute and chronic sinusitis, vasomotor rhinitis. Adjunctive therapy for acute otitis media.

Preparation for surgery in the nasal area and elimination of edema of the nasal mucosa and paranasal sinuses after surgery.

CONTRAINDICATIONS
Hypersensitivity to the components of the drug.

Due to the content of phenylephrine, the drug, like other vasoconstrictors, is contraindicated in atrophic rhinitis, angle-closure glaucoma, as well as in patients taking MAO inhibitors (MAO) or have taken them for the previous 14 days.

INTERACTION WITH OTHER DRUGS AND OTHER INTERACTIONS
The drug is contraindicated in patients taking MAO inhibitors or have taken them in the previous 14 days.

FEATURES OF APPLICATION
The drug, like other sympathomimetics, should be used with caution in patients with a pronounced reaction to adrenergic substances, manifested by such signs as insomnia, dizziness, tremors, cardiac arrhythmias or increased blood pressure.

The drug should not be used continuously for more than 7 days.

As with the use of other vasoconstrictor drugs, the recommended dose of the drug should not be exceeded. Excessive use of the drug, especially for children and the elderly, can cause manifestations of the systemic effect of the drug.

It should be used with caution in patients with cardiovascular diseases, patients with arterial hypertension, hyperthyroidism, diabetes mellitus and patients with bladder neck obstruction (eg, prostatic hypertrophy).

Due to the content of the H 1 -antihistamine dimetindene, the drug should be used with caution in patients with epilepsy.